MAP2K7 and non-small cell lung carcinoma: To further investigate the role of MCL-1 in a larger cohort of KRAS-mutant NSCLC cell lines that included KRAS mutations other than G12C, we tested the MEK inhibitor trametinib in combination with AMG 176 (or the related compound AM-862116).